Melanom, h\u0131zl\u0131 yay\u0131lma kabiliyeti ve kemoterapi gibi klasik tedavilere diren\u00e7 g\u00f6stermesi nedeniyle cildin en agresif kanserlerinden biri olmaya devam ediyor. Deri kanserlerinin yaln\u0131zca %5’ini temsil etmesine ra\u011fmen, bu t\u00fcm\u00f6rlerle ilgili \u00f6l\u00fcmlerin \u00e7o\u011fundan sorumludur. \u00d6zellikle Avrupa, Kuzey Amerika ve Okyanusya’da 60 ya\u015f \u00fcst\u00fc ki\u015filerde son on y\u0131llarda insidans\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde artm\u0131\u015ft\u0131r.<\/p>\n
\u0130mm\u00fcnoterapi, melanomun tedavisinde bir d\u00f6n\u00fcm noktas\u0131 olmu\u015ftur; hastal\u0131kla m\u00fccadele etmek i\u00e7in ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin \u00f6zelliklerinden yararlan\u0131r. Melanomun kanser h\u00fccreleri, genellikle ultraviyole \u0131\u015f\u0131nlar\u0131n\u0131n neden oldu\u011fu hasarlar nedeniyle bir\u00e7ok mutasyona sahiptir. Bu mutasyonlar, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi taraf\u0131ndan tan\u0131nabilen anormal proteinler olu\u015fturur ve bu kanseri, organizman\u0131n do\u011fal savunmalar\u0131n\u0131 uyararak \u00e7al\u0131\u015fan tedavilere \u00f6zellikle duyarl\u0131 hale getirir.<\/p>\n
\u0130mm\u00fcnoterapiler, t\u00fcm\u00f6r h\u00fccrelerinin ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6zetiminden ka\u00e7mak i\u00e7in kulland\u0131klar\u0131 mekanizmalar\u0131 bloke ederek etki eder. \u00d6rne\u011fin, PD-1, CTLA-4 veya LAG-3 proteinlerini hedef alan ila\u00e7lar, kanser h\u00fccrelerini yok edebilen ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccreleri olan T lenfositlerini yeniden aktive eder. Ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktas\u0131 inhibit\u00f6rleri olarak adland\u0131r\u0131lan bu tedaviler, ileri evre melanomlu hastalar\u0131n sa\u011fkal\u0131m\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rm\u0131\u015ft\u0131r. Yap\u0131lan \u00e7al\u0131\u015fmalar, bu terapilerle tedavi edilen baz\u0131 hastalar\u0131n ya\u015fam beklentisinin birka\u00e7 aydan birka\u00e7 y\u0131la uzad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n
Ancak t\u00fcm hastalar ayn\u0131 \u015fekilde yan\u0131t vermemektedir. Baz\u0131lar\u0131 zamanla diren\u00e7 geli\u015ftirirken, baz\u0131lar\u0131 hi\u00e7 tepki vermemektedir. Bu engelleri a\u015fmak i\u00e7in ara\u015ft\u0131rmac\u0131lar, yeni ila\u00e7 kombinasyonlar\u0131 ve h\u00fccresel terapiler veya ki\u015fiselle\u015ftirilmi\u015f a\u015f\u0131lar gibi yenilik\u00e7i yakla\u015f\u0131mlar\u0131 ara\u015ft\u0131rmaktad\u0131r. Bu ilerlemeler, imm\u00fcnoterapilerin etkinli\u011fini art\u0131rmay\u0131 ve bazen ciddi olabilen yan etkileri azaltmay\u0131 ama\u00e7lamaktad\u0131r.<\/p>\n
Bu tedavilerin cerrahi, radyoterapi veya kemoterapi ile birlikte kullan\u0131m\u0131 da ara\u015ft\u0131r\u0131lmaktad\u0131r. Hedef, sonu\u00e7lar\u0131 optimize etmek ve her hastaya, t\u00fcm\u00f6r\u00fcn\u00fcn \u00f6zelliklerine ve genel sa\u011fl\u0131k durumuna g\u00f6re uyarlanm\u0131\u015f \u00e7\u00f6z\u00fcmler sunmakt\u0131r. Bu ilerlemeler sayesinde, bir zamanlar \u00f6l\u00fcmc\u00fcl bir te\u015fhis olarak g\u00f6r\u00fclen metastatik melanom, art\u0131k daha iyi kontrol edilebilen hatta baz\u0131 durumlarda iyile\u015ftirilebilen bir hastal\u0131k haline gelmektedir.<\/p>\n
DOI\u00a0:<\/strong> https:\/\/doi.org\/10.1007\/s11912-026-01750-1<\/a><\/p>\n Titre\u00a0:<\/strong> Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies<\/p>\n Revue : <\/strong> Current Oncology Reports<\/p>\n \u00c9diteur : <\/strong> Springer Science and Business Media LLC<\/p>\n Auteurs : <\/strong> Andrea M. Allen-Tejerina; Periklis Giannakis; Thomas Ho Lai Yau; Christopher R. T. Hillyar; Kathrine S. Rallis<\/p>\n","protected":false},"excerpt":{"rendered":" \u0130mm\u00fcnoterapiler metastatik melanomu tedavisinde d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor mu? Melanom, h\u0131zl\u0131 yay\u0131lma kabiliyeti ve kemoterapi gibi klasik tedavilere diren\u00e7 g\u00f6stermesi nedeniyle cildin en agresif kanserlerinden biri olmaya devam ediyor. Deri kanserlerinin yaln\u0131zca %5’ini temsil etmesine ra\u011fmen, bu t\u00fcm\u00f6rlerle ilgili \u00f6l\u00fcmlerin \u00e7o\u011fundan sorumludur. \u00d6zellikle Avrupa, Kuzey Amerika ve Okyanusya’da 60 ya\u015f \u00fcst\u00fc ki\u015filerde son on y\u0131llarda insidans\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde… Okumaya devam et \u0130mm\u00fcnoterapiler metastatik melanomu tedavisinde d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor mu?<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-14","post","type-post","status-publish","format-standard","hentry","category-saglik","entry"],"_links":{"self":[{"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/posts\/14","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/comments?post=14"}],"version-history":[{"count":1,"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/posts\/14\/revisions"}],"predecessor-version":[{"id":15,"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/posts\/14\/revisions\/15"}],"wp:attachment":[{"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/media?parent=14"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/categories?post=14"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/themedicaltribune.com\/tr\/wp-json\/wp\/v2\/tags?post=14"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}